Trump, Russia sanctions and Middle East tensions
Reports indicate that Pfizer is moving toward submitting an application to the U.S. Food and Drug Administration for approval to use its COVID-19 vaccine in children aged 6 months to 5 years. This comes after results showed approximately 80% effectiveness in preventing infection. The study also demonstrated that the vaccine elicits a strong immune response with mild to moderate side effects. The company believes that vaccinating children in this age group is essential to protect them from the virus.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)